Myriad Sues Pathway for BRCA Testing; Pathway Readying Defense | GenomeWeb

NEW YORK (GenomeWeb) – Myriad Genetics sued Pathway Genomics on June 13 for infringement of its patent claims underlying BRCA1 and BRCA2 genetic testing.

San Diego-based Pathway issued a statement today stating that it will "vigorously defend" itself against that suit. The legal challenge was spurred by Pathway's launch earlier this month of a next-generation sequencing test for gauging alterations in BRCA1 and BRCA2 genes, called BRCATrue.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: transcriptional and translational study of human cytomegalovirus interactions with host cells, spider web DNA study, and more.

The New York Stem Cell Foundation signs a lease for a new space.

Researchers gear up for an international meeting to discuss the ethics of gene editing.

In Nucleic Acids Research this week: personal genome approach to RNA-seq read alignment, hematopoietic Systems Biology Repository, and more.